Kuros Biosciences Ltd. · SIX:KURN
Kuros Biosciences — Investor Day (June 2026)
99 slides from Kuros Biosciences's investor day presentation, Jun 17, 2026
Slide 1: Accelerating into 2026 – Capital Markets Day
Accelerating into 2026 Capital Markets Day June 17, 2026 Ticker: KURN SIX Swiss Stock Exchange 1 1
Slide 2: Disclaimer
Disclaimer This presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, in or into the United States or the United Kingdom, Canada, Australia, Japan,
Slide 3: Meet your hosts
Meet your hosts Carly Dummer Chris Fair Joost de Bruijn, PhD Daniel Geiger Joe Ross Mr. Andy Golberg Chief Financial Officer SVP, Marketing Snr. Director Marketing CEO, Board Member Executive Director and President, Innovation & Strategy OBE MD MBBS FRCS Orthopedic Surgeon The Wellington Hospital, L
Slide 4: Meeting objectives
Meeting objectives STRATEGY Explain how Kuros aims to support short and mid-term revenue and profitability targets through a clear commercial plan and key business transformation initiatives EVIDENCE & INNOVATION Share clinical data, innovation pipeline, and surgeon & patient perspectives that demon
Slide 5: What we'll cover today
What we’ll cover today 01 02 03 04 Global Expanding into Customer Differentiating Commercial new markets engagement through evidence strategy 05 Product innovation 06 A surgeon & patient perspective 07 Business transformation 08 Q&A 5
Slide 6: Vision Mission
Vision Mission To be a trusted global leader with an Kuros To discover, develop advanced orthobiologic portfolio, providing reliable, guiding and deliver innovative clinically proven solutions principles biologic technologies to hospitals, surgeons & their patients 6
Slide 7: First time profitability
First time profitability Accelerating into 2026 from a position of strength: Kuros reached profitability while growing 72% in 2025 7 7
Slide 8: Accelerating into 2026 from a position of strength
Accelerating into 2026 from a position of strength Kuros reached profitability while growing 72% in 2025 Strong Revenue Growth Profitability Milestone Robust Financial Foundation $146.1M Total Medical Device sales $19.6M adjusted EBITDA $19.8M cash, debt-free +72% growth Total Medical Device
Slide 9: MagnetOs now ranked 3rd largest brand by revenue
MagnetOs now ranked 3rd largest brand by revenue U.S. biologics market ranking by brand revenue Rank Company Brand Category 2025 revenue MagnetOs #3 overall 1 Medtronic Infuse Growth factor $887M Growth factor (by revenue) 2 Biocomposites Stimulan* Antibiotic $191M Antibiotic Peptides Synthetic 3 Ku
Slide 10: Global commercial strategy
Global commercial strategy 10
Slide 11: Expanding our presence & developing data to maximize reach
Expanding our presence & developing data to maximize reach Current 2026 Markets Market Targets $8.2B Spine: MagnetOs is indicated for all spinal fusion procedures* unlike many major alternatives, now with $5.5B a product specifically designed for minimally invasive surgery** F&A, Trauma: To our
Slide 12: Consistently taking share from target market categories
Consistently taking share from target market categories $2,500,000,000 100% 1% 2% 3% 5% 6% 5% 6% 90% By revenue: 29% 29% 27% 22% 21% 25% 23% $2,000,000,000 80% P-15 peptides 70% $1,500,000,000 60% CBAs 50% 49% 46% 47% 47% 49% 51% 48% $1,000,000,000 40% Growth factors 30% Synthetics $500,000,000 20%
Slide 13: Significant potential across our target segments: US spine market
Significant potential across our target segments: US spine market Target surgeons Target procedures Opportunity 7,498 ortho and neurosurgeons 400,000 351,525 369,553 968,949 completing spinal 350,000 estimated addressable fusion procedures1 300,000 spine fusion procedures2 250,000 200,000 4,564 surg
Slide 14: Significant potential across our target segments: US F&A fusion market
Significant potential across our target segments: US F&A fusion market Target surgeons Target F&A fusion procedure volumes Opportunity 5,977 orthopedic and podiatric surgeons doing fusions in the foot & ankle1 600,000 598,805 490,296 estimated total 500,000 procedures2,3 400,000 1,818 surgeons compl
Slide 15: Significant potential across our target segments: US trauma market
Significant potential across our target segments: US trauma market Target surgeons Addressable bone graft procedure volumes Opportunity 19,545 active ortho surgeons doing trauma cases (across 500,000 434,412 636,407 all specialties)1 450,000 estimated addressable 400,000 trauma procedures2 350,000 3
Slide 16: Focused on key differentiators that are meaningful to our customers
Focused on key differentiators that are meaningful to our customers Level 1 clinical data: Nothing provides more confidence Superior handling: than a prospective RCT Must be easy to use & stay put Best-in-class educational events: Broad indications: Validation from peers Removes worry Innovation in
Slide 17: Expanding into new markets
Expanding into new markets 17
Slide 18: Kuros is driving success in the fastest growing ortho segments
Kuros is driving success in the fastest growing ortho segments Foot & Ankle Ortho Trauma $474 ASTRA Level I study – Currently enrolling Level III-IV data being collected Extremity focused distribution Extremity/Trauma focused distribution F&A focused medical education Trauma focused medi
Slide 19: An ideal synthetic bone graft for foot & ankle
An ideal synthetic bone graft for foot & ankle Non-union is a clinical and economic problem Industry has focused R&D & clinical evidence elsewhere Lack of extremities focus & investment by competition 1 2-5 *6-8 MAXA spine study (Complete) Efficient + robust handling in OR Novel mode of
Slide 20: A graft focused on bone healing for trauma
A graft focused on bone healing for trauma Highly variable injury types and patient biology contribute to delayed unions and non-unions of fractures in trauma Competitive offerings tend to have singular functions – void filling, stabilizing, or bone growth but lack multi-function versatility 1 2
Slide 21: Customer engagement: Meeting surgeons where they are
Customer engagement: Meeting surgeons where they are 21
Slide 22: Strong engagement & education is key
Strong engagement & education is key Meet the Expert Scientific VIP Initial Kuros Insights and/or Meeting Xchange Symposia Visionaries Journal Club Introduce Educate non-users Deep dive Post-approval Deeper diver into MagnetOs, and new users, group science & data education for peers, science & data,
Slide 23: What are KIX, UNION and VIP events?
What are KIX, UNION and VIP events? Kuros Insights Xchange (Spine) & UNION (Extremities) Non-users, new users, early users Kuros leadership & Key Opinion Leaders (KOLs) sharing science, data, knowledge, and case examples VIP Visionaries KOLs >1 year MagnetOs use Interested in developing stud
Slide 24: Supporting surgeon engagement, product awareness & clinical education
Supporting surgeon engagement, product awareness & clinical education “I left feeling more confident in my choices and more connected to peers tackling similar surgical challenges.” “The format encouraged real discussion – not just lectures. It was refreshing and genuinely impactful on how I approac
Slide 25: Kuros' scientific support sets us apart from the competition
Kuros’ scientific support sets us apart from the competition Surgeon engagement in 2026: • 65 individual meetings with surgeons • 148 surgeons engaged at Journal Clubs, Scientific Symposia, and Fellows dinners • Sponsored 8 fellowships in 2025- 2026 academic year • Surgeon presentations at 5 confere
Slide 26: Differentiating through evidence generation
Differentiating through evidence generation 26
Slide 27: Kuros is going above and beyond to prove efficacy
Kuros is going above and beyond to prove efficacy Regulatory Class FDA Pathway Evidence Required Examples Class III Pre-market approval (PMA)1 Robust Level I human clinical study BMP-2 (Infuse®) P-15 Peptide (PearlMatrixTM, i-FACTOR®) Investigational Device Exemption (IDE) trial Class II 510(k)2
Slide 28: Only products supported by robust published Level I evidence
Only 5 products are supported by robust published Level I evidence Higher fusion rates matter even more in difficult fusion procedures Number of Control arm Product Product Indication Design Timepoint patients Product fusion fusion Category (# levels) (Autograft) Multi-level 1 yr 79% (96%*) 47% (72%
Slide 29: Why is Level I evidence important?
Why is Level 1 evidence important? Level I evidence moves the conversation from product claims to clinical confidence LEVEL I HIGHEST CONFIDENCE Randomized controlled trials with adequate sample size Why it matters in Systematic reviews or meta-analyses of Level I RCTs clinical decisions MODERATE CO
Slide 30: Kuros is leading the way with prospective Level I studies
Kuros is leading the way with prospective Level I studies PROOF PRECISE ASTRA (N=60) (N=100) (N=126) Posterolateral fusion Posterolateral fusion Hindfoot & ankle fusion (PLF) (PLF) MagnetOs MagnetOs MagnetOs Easypack Putty Flex Matrix or Magnetos Putty Easypack Putty vs Trinity Elite (CBA) vs autogr
Slide 31: Independent investigators have proven MagnetOs efficacy in various complex procedures
Independent investigators have proven MagnetOs efficacy in various complex procedures Anterior/interbody fusion: Posterolateral fusion: Less challenging Most challenging Fusion rates Fusion rates Nunley Ambispective ALIF, LLIF, 62 pts 90% 50% patients 3+ comorbidities 12 months 79% Kruyt Prospective
Slide 32: With many more investigator-led studies underway
With many more investigator-led studies underway Alveolar Cleft (vs. Autograft) ACDF 80 Patients 20 patients PCF (vs. DBM + Autograft) PLF 71 Patients ALIF / LLIF Up to 175 Patients PLF 26 Patients (vs. BMP-2) Target 156 Patients Scoliosis ALIF (vs. Autograft) (vs. Bioglass) 140 Patients 100 Patient
Slide 33: Fusion rate is just one criteria that surgeons are measuring
Fusion rate is just one criteria that surgeons are measuring Fusion rate % Fusion mass Speed to (volume) fusion How do the above criteria differ in high-risk patients with various comorbidities? 33
Slide 34: Surgeons are questioning how much bone is actually produced
Surgeons are questioning how much bone is actually produced MagnetOs is volumetrically stable compared to various well-known grafts on the market – including autograft†1 Day 0 Fusion mass 12 weeks* 3D-reconstructions 12 weeks 10.0 10 9.6 MagnetOs 10 cm³ implanted 5.7 cm³ 5 3.0 3.0 Autograft Novabone
Slide 35: MagnetOs data addresses the emerging question of fusion speed
MagnetOs data addresses the emerging question of fusion speed Demonstrated high fusion rates by 6 months in a high-risk patient population1 Dr. Mark Eskander High fusion rates were observed before 6 months and remained high after 6 months with 67% high risk patients (X-ray fusion assessment)1 Orthop
Slide 36: Surgeons are seeing increasingly high-risk patient populations
Surgeons are seeing increasingly high-risk patient populations MagnetOs showed 94% fusion in patients with common nonunion high risk factors1 Patient reported outcomes demonstrated a substantial improvement in pain and functional grade 94.4% fusion rate observed between 12 – 14 months among Dr. Just
Slide 37: Innovating in evidence generation to support surgeon decisions
Innovating in evidence generation to support surgeon decisions 37
Slide 38: Why is fusion assessment so challenging?
Why is fusion assessment so challenging? Radiopaque grafts Timing is everything No single answer Some bone graft materials appear Early post-op images look very Fusion confidence is rarely built on white on X-ray – making it difficult to different from later follow-up because one image alone. distin
Slide 39: No imaging modality is perfect... nor are patients
No imaging modality is perfect... nor are patients Limitations of imaging modalities Patient variables X-ray, CT, SPECT/CT and MRI have unique limitations Patient factors like bone quality, comorbidities and age can influence bone healing and fusion timing Smoking Respiratory disease Obesity Heart d
Slide 40: Why does histology matter?
Why does histology matter? Transverse Bone graft process (TP) Autograft Novabone Putty® Vitoss® BA2X Radiodensity/opacity does not guarantee presence of bone Ovine instrumented posterolateral fusion after 12 Weeks. *MagnetOs has been proven to generate more predictable fusions than two commercially
Slide 41: Kuros continues to innovate with evidence generation
Kuros continues to innovate with evidence generation to help solve for the challenges that surgeons face Together, this evidence portfolio helps demonstrate not only that fusion occurs, but how and where new bone forms NEW 1 Benchtop data 2 Preclinical (animal) 3 Clinical (human) 4 Surgical explorat
Slide 42: Case Presentation: Surgical exploration & histology
Case Presentation: Surgical exploration & histology Dr. R Todd Allen 42
Slide 43: Scoliosis correction and fusion with MagnetOs Putty
Scoliosis correction and fusion with MagnetOs Putty Dr. Todd Allen, Professor, Endowed Chair in Spinal Surgery and Spine Fellowship Director, Department of Orthopedic Surgery, UC San Diego School of Medicine 28-year-old female Preoperative X-ray 22 months postoperative X-rays Diagnosis Patient pre
Slide 44: Case example references and disclosures
Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings. 44 This case example is the surgical technique of Dr. Allen and provided for informational purposes only. Dr. Allen is a paid consultant for Kuros. Hatfield C, et al. .JOJ Case Stud
Slide 45: Intraoperative observations
Intraoperative observations: Robust fusion mass on MagnetOs side Visual confirmation of structural integrity Tactile feedback: solidified bone on tapping Biopsies taken bilaterally Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and wa
Slide 46: Histological analysis showed mature lamellar bone
Histological analysis of patient tissue biopsied from the lumbar region showed mature lamellar bone Outcome: Histology Lateral view (from the side) Axial view (from above) Biopsy taken from above the rod AI-generated images for illustrative purposes only Native bone G = Residual MagnetOs Granule Mag
Slide 47: Case Presentation: Surgical exploration & histology
Case Presentation: Surgical exploration & histology Dr. Faheem Sandhu 47
Slide 48: MagnetOs Putty in a thoracic kyphosis case
MagnetOs Putty in a thoracic kyphosis case Dr. Faheem Sandhu, Director of Spine Surgery, MedStar Georgetown University Hospital 65 year-old male Relevant medical history H/O SVT, HTN, osteopenia, obesity, bronogenic lung CA, COPD, L4-5 discectomy x 3 Fell in September 2024 on his back Severe b
Slide 49: T7-8 corpectomies, T5-T10 PSF postoperative
T7-8 corpectomies, T5-T10 PSF – 5 months postoperative 20cc of MagnetOs Putty used standalone grafts? Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings. 49 This case example is the surgical technique of Dr. Sandhu and provided for i
Slide 50: Severe pain several weeks after surgery: CT myelogram
Severe pain several weeks after surgery: CT myelogram Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings. 50 This case example is the surgical technique of Dr. Sandhu and provided for informational purposes only. Dr. Sandhu is a paid
Slide 51: Surgery to remove hardware, explore fusion
Surgery to remove hardware, explore fusion 11 months postoperative Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings. 51 This case example is the surgical technique of Dr. Sandhu and provided for informational purposes only. Dr. San
Slide 52: Intraoperative pictures
Intraoperative pictures Image following removal of tissue for biopsy Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings. 52 This case example is the surgical technique of Dr. Sandhu and provided for informational purposes only. Dr. S
Slide 53: Tissue removed for biopsy shows lamellar bone
Tissue removed for biopsy shows lamellar bone 40X 100X Biopsy shows lamellar bone with marrow spaces 200X 200X Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings. 53 This case example is the surgical technique of Dr. Sandhu and provi
Slide 54: Product innovation
Product innovation 54
Slide 55: Innovation is our catalyst for sustainable revenue growth
Innovation is our catalyst for sustainable revenue growth Kuros has a disciplined investment strategy for R&D 2026 product line extensions planned, informed by market research and voice-of-customer insights, broadening MagnetOs utilization across additional procedures and surgical techniques Eva
Slide 56: Continuously expanding U.S. indications
Continuously expanding U.S. indications NEW MagnetOs MagnetOs MagnetOs MagnetOs MagnetOs Indication: MIS Easypack Putty Flex Matrix Putty Granules With BMA Posterolateral spine Standalone Standalone Standalone Standalone & autograft Intervertebral disc With BMA Standalone Standalone Standalone With
Slide 57: MagnetOs MIS new product development process
MagnetOs MIS new product development process based on unmet clinical needs NEED #1 EXAMPLE: NEW SOLUTION Initial product development to address an unmet surgeon need UNMET NEED Surgeons desired optimized delivery of MagnetOs in MIS procedures Need Develop identified prototypes/data ACCESS MARKET NEE
Slide 58: MagnetOs supports improved surgical precision for MIS
MagnetOs supports improved surgical precision for Minimally Invasive Surgery (MIS) procedures: What is MIS and why does it matter? Traditional Open Surgery Minimally Invasive Surgery TLIF1 (MIS) TLIF1 TLIF = Transforaminal MIS Potential Benefits2: Lumbar Interbody Fusion − Less blood loss from surge
Slide 59: New product launch revolutionizes MIS
New product launch revolutionizes MIS: A smarter way to deliver bone graft MagnetOs MIS is the only MIS bone graft delivery system that is: − Sterile1 − Prefilled1 − Contains no human tissue1 − Containing a bone graft whose mechanism of action (MOA) is supported by Level I clinical evidence2 All whi
Slide 60: Incremental MagnetOs MIS product development in progress
Incremental MagnetOs MIS product development in progress NEED EXAMPLE #2: PRODUCT ENHANCEMENT Incremental product enhancement to improve precision of MagnetOs MIS delivery REFINEMENT NEED Surgeons wanted more precise placement and control in tighter spaces Need Develop identified prototypes/data PRE
Slide 61: Adapting to meet surgeon needs
Adapting to meet surgeon needs First (current) generation Second generation Expected launch 1H 2027 Spine-focused + extremities/trauma capable Smaller granules for smaller cavities Conical and rectangular applicator tips added Volume-dispensed markings added 61
Slide 62: MagnetOs MIS Precision delivers graft where others can't
MagnetOs MIS Precision delivers graft where others can’t 62
Slide 63: MagnetOs Flex Matrix: responding to customer needs
MagnetOs Flex Matrix: responding to customer needs NEED EXAMPLE #:3 PRODUCT ENHANCEMENT Expand MagnetOs Flex Matrix size options CUSTOMER NEED Surgeons wanted larger MagnetOs Flex Matrix sizes for PLF Need Develop identified prototypes/data SIZING MARKET NEED BUILD VALIDATE FDA CLEARANCE “I need a l
Slide 64: MagnetOs Flex Matrix portfolio expansion
MagnetOs Flex Matrix portfolio expansion: Fast growing formulation New sizes coming in 2H 2026! Longer: deformity procedures More volume: 20cc procedures Thicker: firmer strip preferences 64
Slide 65: So what's next? Diving into the broader bone void filler market
So what’s next? Diving into the broader bone void filler market Resorbable, settable bone void fillers Polymethylme Antibiotic-eluting Regenerative Settable bone Dead space thacrylate settable bone void bone graft void filler management (PMMA) bone filler cement Primary Bone formation Defect support
Slide 66: Defining the resorbable, settable bone void filler market opportunity
Defining the resorbable, settable bone void filler market opportunity Resorbable, settable bone void filler market $489M total U.S. market U.S. market size by segment (2025) Regenerative Antibiotic-eluting Antibiotic beads for 250 $212M bone void fillers bone void fillers dead space management 200 $
Slide 67: Resorbable, settable bone void filler: Focus & opportunity
Resorbable, settable bone void filler: Focus & opportunity ACTIVE SHORT TERM Targeted Extremity Trauma Procedures 800000 706,502 Total Group CAGR – 2.2% 653,917 671,426 688,959 700000 618,911 636,407 Lower Extremity CAGR Distal Femur 2.5% 600000 Prox Tibia 1.7% Distal Tibia 2.2% 500000 Upper Extremi
Slide 68: Expanding the portfolio and business development projects pipeline
Expanding the portfolio and business development projects pipeline Balanced portfolio strategy delivering near-term revenue and long-term growth SHORT TERM MID TERM LONG TERM 0-2 years 2-5 years 5+ years Launch Develop Explore Resorbable, settable Future product MagnetOs MIS Gen2 bone void filler +
Slide 69: A surgeon & patient perspective: Why MagnetOs in F&A
A surgeon & patient perspective: Why MagnetOs in F&A 69
Slide 70: MagnetOs in Foot & Ankle: The Developing Opportunity
MagnetOs in Foot & Ankle: The Developing Opportunity Mr. Andrew Goldberg, OBE, MD, FRCS (Tr&Orth). Consultant Orthopaedic Foot and Ankle Surgeon for Adults & Children The Wellington Hospital, London Visiting Professor Imperial College London Honorary Associate Clinical Professor, University College
Slide 71: Disclosures
MagnetOs: A UK Extremity Surgeon’s Perspective Disclosures Mr. Goldberg is a paid consultant for Kuros Biosciences. The opinions expressed are solely those of the presenter and do not necessarily represent the views of affiliated institutions, employers or professional bodies. 71
Slide 72: Today's Journey
MagnetOs: A UK Extremity Surgeon’s Perspective Today’s Journey 01 The Unmet Need Why foot & ankle bone healing is uniquely challenging 02 The Market Opportunity A large, growing, underpenetrated segment 03 Evidentiary Foundation What the spine data tells us - and why it transfers 04 Early Foot & Ank
Slide 73: The Unmet Need
MagnetOs: A UK Extremity Surgeon’s Perspective 01 | The Unmet Need Why foot & ankle bone healing is uniquely challenging 73
Slide 74: The Unmet Need
MagnetOs: A UK Extremity Surgeon’s Perspective The Unmet Need Hostile Biology Poor vascularity, high mechanical load, and systemic comorbidities combine to create one of the most demanding fusion environments in orthopaedics. Non-union rates can reach 40% Enormous Economic Burden Diabetic foot care
Slide 75: The Market Opportunity
MagnetOs: A UK Extremity Surgeon’s Perspective The Market Opportunity The global bone graft substitutes market is worth $3.2B ~60M £837M+ NHS annual diabetic Diabetics in Europe¹ foot care cost² No CE Mark Dominant biologics Favourable UK/EU player in foot & ankle regulatory pathway growing at ~8% C
Slide 76: Evidentiary Foundation
MagnetOs: A UK Extremity Surgeon’s Perspective 03 | Evidentiary Foundation What the spine data tells us 76
Slide 77: Evidentiary Foundation
MagnetOs: A UK Extremity Surgeon’s Perspective Evidentiary Foundation The Mechanism is Not Spine-Specific. MagnetOs bone graft works through osteoinduction — harnessing the immune system via submicron surface MAXA Level I RCT¹ topography, NeedleGrip surface topography. That cellular 79% machinery is
Slide 78: Early Foot & Ankle Experience
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Patient Profile Transparency first: Complex hindfoot and ankle fusions in diabetic, immunocompromised, and • Formal RCT data for MagnetOs bone graft in foot & revision cases — exactly where legacy products fall short. Non-u
Slide 79: Early Foot & Ankle Experience: Case Example #1
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #1 - MagnetOs Putty in an ankle arthrodesis1 AP Preoperative CT Lateral Preoperative CT Patient 55-year-old male History Right ankle fracture dislocation 20 years prior Diagnosis Right posttraumatic ankle arthr
Slide 80: Early Foot & Ankle Experience: Case Example #1
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #1 - MagnetOs Putty in an ankle arthrodesis1 Preoperative 3D scan Patient 55-year-old male History Right ankle fracture dislocation 20 years prior Diagnosis Right posttraumatic ankle arthritis Procedure Tibiota
Slide 81: Early Foot & Ankle Experience: Case Example #1
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #1 - MagnetOs Putty in an ankle arthrodesis1 Immediate AP postoperative X-ray Immediate lateral postoperative X-ray Please refer to the Instructions for Use for a full list of indications, contraindications, pr
Slide 82: Early Foot & Ankle Experience: Case Example #1
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #1 - MagnetOs Putty in an ankle arthrodesis1 AP 6 months postoperative X-ray Lateral 6 months postoperative X-ray AP and lateral X-ray images 6 months postoperatively demonstrate hardware in good position with
Slide 83: Early Foot & Ankle Experience: Case Example #2
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #2 - MagnetOs Putty in a bone cyst case2 Patient Preoperative CT 32-year-old male Diagnosis 1. Right chronic ankle instability 2. Incidental finding of calcaneal cyst Procedure 1. Lateral ankle ligament reconst
Slide 84: Early Foot & Ankle Experience: Case Example #2
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #2 - MagnetOs Putty in a bone cyst case2 Intraoperative images Lateral ligament reconstruction, and creation of a 1.5cm square window Bone cyst was revealed, material was curated out and sent to Histology Pleas
Slide 85: Early Foot & Ankle Experience: Case Example #2
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #2 - MagnetOs Putty in a bone cyst case2 Intraoperative images Space was completely compacted with Window was replaced and incision was closed 13cc of MagnetOs Putty Please refer to the Instructions for Use for
Slide 86: Early Foot & Ankle Experience: Case Example #2
MagnetOs: A UK Extremity Surgeon’s Perspective Early Foot & Ankle Experience Case Example #2 - MagnetOs Putty in a bone cyst case2 6 weeks postoperative X-ray Lateral X-ray image 6 weeks postoperatively demonstrates signs of trabecular bone formation of the bone void filled with MagnetOs Putty 13cc.
Slide 87: Case for Adoption
MagnetOs: A UK Extremity Surgeon’s Perspective Case for Adoption How Adoption Happens in UK/EU The Hospital Economics Case — BOFAS & EFAS Networks — Cost per case KOL presentations drive adoption faster than any direct sales force Incremental premium vs. legacy product is modest vs. revision surgery
Slide 88: Clinical Value Proposition
MagnetOs: A UK Extremity Surgeon’s Perspective Clinical Value Proposition 1. The Problem is Real & Growing 2. The Market is Open 3. The Biology is Proven Non-union, failed fusion, and diabetic foot disease No dominant biologics player has established The MAXA RCT demonstrated MagnetOs are large, exp
Slide 89: A UK Extremity Surgeon's Perspective: quote
MagnetOs: A UK Extremity Surgeon’s Perspective What I can tell you is this: I adopted Kuros Biosciences’ MagnetOs bone graft because the biological rationale was strong, and the early clinical results consistently supported its continued use. In my experience, that is how many clinicians evaluate ne
Slide 90: Thank you
MagnetOs: A UK Extremity Surgeon’s Perspective Thank you 90
Slide 91: Business transformation: Scaling the business to compound enterprise value
Business transformation: Scaling the business to compound enterprise value 91
Slide 92: Driving the business model through transformation and optimization
Driving the business model through transformation and optimization What we’ve built What we’re building next STRATEGY Functional Functional (People & governance) (People & governance) Sales & Marketing FRONT END Build up of specialized teams (extremities, IT) Accelerated product engineering cycl
Slide 93: Global supply chain optimization supports scalable growth
Global supply chain optimization supports scalable growth Dual-site manufacturing (Alpharetta + Bilthoven) • Creation of resilient, scalable global supply chain • Reduction of operational and transportation costs Bilthoven, NL • Lowers tariff exposure EU demand & strategic markets Alpharetta, GA (U.
Slide 94: Manufacturing & digital transformational integration
Manufacturing & digital transformational integration New production site & ERP integration create foundation for connected, efficient, multi-site operations 2026 Foundational stage ERP / MRP launch US site H2 launch NL site relocation 2027 Emergent stage US ramp-up to full end-to-end manufac
Slide 95: Dual manufacturing and global MRP improve scalability and cost efficiency
Dual manufacturing and global MRP improve scalability and cost efficiency ERP-enabled visibility and localized production help reduce shipping costs, inventory burden, and tariff exposure while supporting scalable growth BENEFITS FLOW 1 Foundation 2 Operational benefits 3 Financial impact Systems, s
Slide 96: Digitalization of front-end strengthens back-end business steering
Digitalization of front-end strengthens back-end business steering Driving measurable impact on both top and bottom line DIGITAL INPUTS DECISION MAKING BUSINESS IMPACT Real-time front-end visibility connects Sales digitalization sales activity, shipment visibility, Faster cash collection invoicing a
Slide 97: Transforming structure to drive economies of scale & operational leverage
Transforming structure to drive economies of scale & operational leverage All three drivers progress in parallel, the emphasis shifts over time EARLY MID-TERM LATE FUTURE OPERATIONAL LEVERAGE DRIVERS EMPHASIS EMPHASIS EMPHASIS Foundational Qualitative Value REVENUE SCALE investments growth generatio
Slide 98: From breakout growth to scalable leadership
From breakout growth to scalable leadership Building a springboard to support $300M+ by 2028* Operating platform built from 2023 – 2025 is expected to support revenue growth and potential margin expansion from 2026 through 2028 1. Expanding access drives volume growth IDN approvals and distributor
Slide 99: Thank you
Thank you 99 MAT-0382 99